Sigma Pharmaceuticals Forecast, price target & analysts
Sigma Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Sigma Pharmaceuticals Classifications & Recommendation:
Sigma Pharmaceuticals Price Target
| Target Price | AUD2.58 |
| Price | AUD2.94 |
| Deviation |
12.24%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Sigma Pharmaceuticals 2026 .
The average Sigma Pharmaceuticals target price is AUD2.58.
This is
12.24%
register free of charge
AUD3.00
2.04%
register free of charge
AUD2.05
30.27%
register free of charge
|
|
| A rating was issued by 7 analysts: 1 Analysts recommend Sigma Pharmaceuticals to buy, 2 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sigma Pharmaceuticals stock has an average upside potential 2026 of
12.24%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Jan '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion AUD | 3.32 | 4.43 |
| 9.24% | 33.30% | |
| EBITDA Margin | -1.31% | 1.92% |
| 24.57% | 246.19% | |
| Net Margin | 0.00% | 1.01% |
5 Analysts have issued a sales forecast Sigma Pharmaceuticals 2025 . The average Sigma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Sigma Pharmaceuticals EBITDA forecast 2025. The average Sigma Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Jan '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share AUD | 0.00 | 0.03 |
| P/E | 105.03 | |
| EV/Sales | 7.73 |
Based on analysts' sales estimates for 2025, the Sigma Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Sigma Pharmaceuticals...
Current Sigma Pharmaceuticals Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| MACQUARIE RESEARCH | Locked ➜ Locked | Locked | Nov 18 2024 |
| SHAW AND PARTNERS | Locked ➜ Locked | Locked | Aug 28 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
MACQUARIE RESEARCH: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
SHAW AND PARTNERS: Locked ➜ Locked
|
Aug 28 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
